Literature DB >> 15254764

Reduced intestinal inflammation induced by dextran sodium sulfate in interleukin-6-deficient mice.

Yuji Naito1, Tomohisa Takagi, Kazuhiko Uchiyama, Masaaki Kuroda, Satoshi Kokura, Hiroshi Ichikawa, Rie Yanagisawa, Ken-Ichiro Inoue, Hirohisa Takano, Masahiko Satoh, Norimasa Yoshida, Takeshi Okanoue, Toshikazu Yoshikawa.   

Abstract

Interleukin-6 (IL-6) is a multifunctional cytokine secreted by various cells, and is involved in the acute phase response and the immune response through T and B cell activation. To further define the role of IL-6 in intestinal inflammation, we studied the effects of dextran sulfate sodium (DSS) administration in mice with targeted deletions of the IL-6 gene. Acute colitis was induced in female IL-6-/- and IL-6+/+ mice by giving 4.5% DSS orally in drinking water for 8 days. The colonic mucosal injury and inflammation was evaluated based on survival rate, body-weight changes, total colon length and histological findings. Colonic mRNA expression for tumor necrosis factor (TNF)-alpha, IL-6, IL-10 and inducible nitric oxide synthase (iNOS) was measured by RT-PCR. Colonic IL-6 mRNA levels of wild-type mice continued to increase throughout the study period. At each assessment, colonic injury was significantly attenuated in DSS-treated IL-6-/- mice compared with DSS-treated IL-6+/+ mice. Histological study also showed a reduced infiltration of inflammatory cells, especially neutrophils, and mucosal cell disruption in DSS-treated IL-6-/- mice compared with DSS-treated IL-6+/+ mice. In the colons of DSS-treated IL-6-/- mice, the expression of both TNF-alpha mRNA and iNOS mRNA was reduced on day 5. In contrast, IL-10 mRNA expression was enhanced compared with DSS-treated IL-6+/+ mice. In conclusion, DSS-induced inflammation appears to be significantly inhibited in IL-6-/- mice compared to wild-type mice. These data suggest that persistent and marked blockade of IL-6 bioactivity provides some beneficial effects on intestinal inflammation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254764

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  31 in total

1.  The specific JNK inhibitor SP600125 targets tumour necrosis factor-alpha production and epithelial cell apoptosis in acute murine colitis.

Authors:  Kiran Assi; Rex Pillai; Antonio Gómez-Muñoz; David Owen; Baljinder Salh
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

2.  Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fibrinogen.

Authors:  Kris A Steinbrecher; Netanel A Horowitz; Elizabeth A Blevins; Kelley A Barney; Maureen A Shaw; Eleana Harmel-Laws; Fred D Finkelman; Matthew J Flick; Malinda D Pinkerton; Kathryn E Talmage; Keith W Kombrinck; David P Witte; Joseph S Palumbo
Journal:  Cancer Res       Date:  2010-03-16       Impact factor: 12.701

3.  The tumor necrosis factor family member TNFSF14 (LIGHT) is required for resolution of intestinal inflammation in mice.

Authors:  Petra Krause; Sonja P Zahner; Gisen Kim; Raziyah B Shaikh; Marcos W Steinberg; Mitchell Kronenberg
Journal:  Gastroenterology       Date:  2014-02-19       Impact factor: 22.682

4.  cEBP Homologous Protein Expression in Macrophages Regulates the Magnitude and Duration of IL-6 Expression and Dextran Sodium Sulfate Colitis.

Authors:  Shyamasree Datta; Natilibeth Barrera; Paul G Pavicic; Chenyang Zhao; Michael Freeman; Booki Min; Thomas Hamilton
Journal:  J Interferon Cytokine Res       Date:  2015-07-02       Impact factor: 2.607

5.  Role of interleukin 15 in colitis induced by dextran sulphate sodium in mice.

Authors:  K Yoshihara; T Yajima; C Kubo; Y Yoshikai
Journal:  Gut       Date:  2005-09-14       Impact factor: 23.059

6.  IL-6-dependent mucosal protection prevents establishment of a microbial niche for attaching/effacing lesion-forming enteric bacterial pathogens.

Authors:  Sara M Dann; Martina E Spehlmann; Dustin C Hammond; Mitsutoshi Iimura; Koji Hase; Lillian J Choi; Elaine Hanson; Lars Eckmann
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

7.  Interleukin-19 contributes as a protective factor in experimental Th2-mediated colitis.

Authors:  Yasuyuki Fujimoto; Yasu-Taka Azuma; Yukiko Matsuo; Mitsuru Kuwamura; Nobuyuki Kuramoto; Mariko Miki; Naoki Azuma; Midori Teramoto; Kazuhiro Nishiyama; Takeshi Izawa; Hidemitsu Nakajima; Tadayoshi Takeuchi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-12-09       Impact factor: 3.000

8.  Cutting edge: IL-6 is a marker of inflammation with no direct role in inflammasome-mediated mouse models.

Authors:  Matthew D McGeough; Carla A Pena; James L Mueller; Derek A Pociask; Lori Broderick; Hal M Hoffman; Susannah D Brydges
Journal:  J Immunol       Date:  2012-08-17       Impact factor: 5.422

9.  A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis.

Authors:  Ryan Ungaro; Masayuki Fukata; David Hsu; Yasmin Hernandez; Keith Breglio; Anli Chen; Ruliang Xu; John Sotolongo; Cecillia Espana; Julia Zaias; Greg Elson; Lloyd Mayer; Marie Kosco-Vilbois; Maria T Abreu
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-04-09       Impact factor: 4.052

10.  Interleukin-6 mediates the platelet abnormalities and thrombogenesis associated with experimental colitis.

Authors:  Elena Y Senchenkova; Shunsuke Komoto; Janice Russell; Lidiana D Almeida-Paula; Li-Sue Yan; Songlin Zhang; D Neil Granger
Journal:  Am J Pathol       Date:  2013-05-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.